MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 142 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 1.87 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $14,337 | +139.7% | 51,173 | +128.5% | 0.02% | +137.5% |
| Q1 2024 | $5,981 | +40.9% | 22,399 | +22.1% | 0.01% | +33.3% |
| Q4 2023 | $4,245 | +75.2% | 18,347 | +10.6% | 0.01% | +100.0% |
| Q3 2023 | $2,423 | -28.2% | 16,594 | +13.7% | 0.00% | -25.0% |
| Q2 2023 | $3,373 | -20.4% | 14,600 | -16.6% | 0.00% | -33.3% |
| Q1 2023 | $4,240 | -32.4% | 17,502 | -19.0% | 0.01% | -33.3% |
| Q4 2022 | $6,273 | -99.5% | 21,613 | +22.9% | 0.01% | +350.0% |
| Q3 2022 | $1,143,000 | -9.0% | 17,589 | +0.2% | 0.00% | 0.0% |
| Q2 2022 | $1,256,000 | +52.2% | 17,553 | +108.8% | 0.00% | +100.0% |
| Q1 2022 | $825,000 | +18.7% | 8,406 | +2.6% | 0.00% | 0.0% |
| Q4 2021 | $695,000 | +5.9% | 8,196 | -0.3% | 0.00% | 0.0% |
| Q3 2021 | $656,000 | -31.8% | 8,218 | -16.7% | 0.00% | 0.0% |
| Q2 2021 | $962,000 | +1.6% | 9,871 | +21.9% | 0.00% | 0.0% |
| Q1 2021 | $947,000 | +5.2% | 8,100 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $900,000 | -6.4% | 8,100 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $962,000 | +4.9% | 8,100 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $917,000 | +76.0% | 8,100 | +3.8% | 0.00% | 0.0% |
| Q1 2020 | $521,000 | -26.7% | 7,800 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $711,000 | -9.4% | 7,800 | -14.3% | 0.00% | 0.0% |
| Q3 2019 | $785,000 | -7.5% | 9,100 | +12.3% | 0.00% | 0.0% |
| Q2 2019 | $849,000 | -4.5% | 8,100 | +14.1% | 0.00% | 0.0% |
| Q1 2019 | $889,000 | +11.1% | 7,100 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $800,000 | -51.5% | 7,100 | -7.8% | 0.00% | -50.0% |
| Q3 2018 | $1,649,000 | -9.3% | 7,700 | +18.5% | 0.00% | 0.0% |
| Q2 2018 | $1,818,000 | +245.6% | 6,500 | +44.4% | 0.00% | +100.0% |
| Q1 2018 | $526,000 | +27.4% | 4,500 | 0.0% | 0.00% | – |
| Q4 2017 | $413,000 | +37.2% | 4,500 | -32.8% | 0.00% | – |
| Q3 2017 | $301,000 | +176.1% | 6,700 | 0.0% | 0.00% | – |
| Q2 2017 | $109,000 | – | 6,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| University of Wisconsin Foundation | 73,487 | $17,003,422 | 28.29% |
| Tao Capital Management LP | 130,529 | $30,202 | 27.63% |
| Paulson & Co. | 1,105,741 | $255,846,353 | 23.09% |
| AlpInvest Partners B.V. | 211,488 | $48,934,093 | 11.18% |
| Bain Capital Life Sciences Investors, LLC | 324,619 | $75,110,344 | 7.20% |
| Avoro Capital Advisors LLC | 1,888,888 | $437,050,905 | 6.04% |
| Propel Bio Management, LLC | 30,032 | $6,948,804 | 5.76% |
| Baker Brothers Advisors | 1,969,798 | $455,771,861 | 5.19% |
| Rosalind Advisors, Inc. | 25,000 | $5,784,500 | 4.76% |
| TCG Crossover Management, LLC | 179,917 | $41,629,195 | 4.62% |